For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Dulaglutide - Diabetes Mellitus
PAD Profile : Dulaglutide - Diabetes Mellitus
Traffic Light Status
Status 1 of 3.
- Subcutaneous injection (sc)
Status 2 of 3.
- Not Specified
Status 3 of 3.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Dapagliflozin
- Exenatide
- Insulin detemir
- Liraglutide
- Pioglitazone hydrochloride
- Sitagliptin
- Vildagliptin
- Saxagliptin
- Linagliptin
- Alogliptin
- Empagliflozin
- Xultophy
- Metformin hydrochloride
- Insulin Glargine - Toujeo
- Insulin glargine - Abasaglar
- Insulin degludec
- Insulin aspart - NovoRapid
- Insulin glulisine - Apidra
- Insulin Lispro - Admelog
- Gliclazide
- Acarbose
- Insulin Aspart - Trurapi
- Repaglinide
- Glimepiride
- Glipizide
- Glibenclamide
- Tolbutamide
- Albiglutide
- Insulin pump - Type 1 diabetes
- Semaglutide
- Ertugliflozin
- Suliqua (Insulin glargine/lixisenatide)
- Glyxambi (Linagliptin/empagliflozin)
- Sotagliflozin
- Semaglutide (oral)
- Tirzepatide
- Metformin hydrochloride/sitagliptin
- Metformin hydrochloride/vildagliptin
- Alogliptin/metformin
- Linagliptin/metformin
- Empagliflozin/metformin
- Canagliflozin/metformin
- Dapagliflozin/metformin
- Saxagliptin/dapagliflozin
- Metformin hydrochloride/pioglitazone
- Diazoxide
- Glucose
- Soluble insulin - Hypurin porcine neutral
- Insulin Lispro - Lyumjev
- Insulin Lispro - Humalog
- Insulin Aspart - Fiasp
- Soluble insulin - Humulin R
- Soluble insulin - Humulin S
- Soluble insulin - Actrapid
- Insulin glargine - Lantus
- Insulin glargine - Semglee
- Isophane (neutral insulin) - hypurin porcine 30/70
- Biphasic Isophane Insulin - Humulin M3
- Biphasic Insulin Aspart - Novmix 30
- Biphasic Lispro Insulin - Humalog Mix 25
- Biphasic Lispro Insulin - Humalog Mix 50
- Isophane Insulin - Hypurin Porcine Isophane
- Isophane Insulin - Insulatard
- Isophane Insulin - Humulin I
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
Dulaglutide continues to be the preferred GLP-1 where weekly injection is indicated (due to it no longer having black triangle status)
Semaglutide is an alternative option for weekly injection.
Liraglutide is an alternative 1st-line (for patients who wish to have a daily injection)
Lixisenatide is no longer a preferred treatment but remains an option.
Treatment with GLP-1s should be reviewed at 6 months. If there is no beneficial metabolic response (defined in NICE guidance), then stop treatment, and consider alternative treatment (usually insulin initiation) in line with NICE guidance